Merck KGaA enters licence agreement with Abbisko Therapeutics for Phase III ABSK 021 (pimicotinib) for the treatment of tenosynovial giant cell tumor.
Merck KGaA, a leading science and technology company, announced a license agreement with Abbisko Therapeutics Co. Ltd, Shanghai, China, for pimicotinib (ABSK 021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT)
TGCT is a benign tumor of the joints that can cause swelling, pain, stiffness, and limited mobility of the affected joints. Treatment options for this disease, which can seriously affect patients’ quality of life, are very limited. The agreement grants Merck a license to commercialize pimicotinib in mainland China, Hong Kong, Macau and Taiwan, with an option for rest of world.
Pimicotinib is an orally administered, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor (CSF-1R) currently being evaluated in a global Phase III clinical trial as a potential therapy for TGCT. No drugs are currently approved in China for the disease, and only one medicine has been approved in the U.S.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins